Skip to main content

Table 3 Correlation between nuclear REDD1 expression and clinicopathologic factor

From: Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma

Characteristic

REDD1 expression

Total No.

χ2

P-value

Negative

Positive

No. (%)

No. (%)

Age

0.508*

 20-

5(83.3)

1(16.7)

6

  

 30-

6(60.0)

4(40.0)

10

  

 40-

37(80.4)

9(19.6)

46

  

 50-

49(80.3)

12(19.7)

61

  

 60-

66(85.7)

11(14.3)

77

  

 70-

19(76.0)

6(24.0)

25

  

 80-

4(100.0)

0(0.0)

4

  

Stage

3.4

0.334

 Stage I

25(75.8)

8(24.2)

33

  

 Stage II

20(71.4)

8(28.6)

28

  

 Stage III

115(84.6)

21(15.4)

136

  

 Stage IV

26(81.3)

6(18.8)

32

  

Histologic type

0.043*

 Serous carcinoma

105(84.0)

20(16.0)

125

  

 Mucinous carcinoma

6(100.0)

0(0.0)

6

  

 Endometrioid carcinoma

24(77.4)

7(22.6)

31

  

 Clear cell carcinoma

7(50.0)

7(50.0)

14

  

 Mixed-type carcinoma

44(83.0)

9(17.0)

53

  

Ascites

3.633

0.161

 Yes

108(78.8)

29(21.2)

137

  

 No

49(80.3)

12(19.7)

61

  

 Unknown

29(93.5)

2(6.5)

31

  

Chemotherapy response

0.801*

 Completely Responders

130(81.8)

29(18.2)

159

  

 Partial responders

34(82.9)

7(17.1)

41

  

 Non responders

14(73.7)

5(26.3)

19

  

 NC/URa

8(80.0)

2(20.0)

10

  

CA125

0.750*

  < 500

50 (78.1)

14 (21.9)

64

  

  ≥ 500

54 (83.1)

11 (16.9)

65

  

 Unknown

82 (82.0)

18 (18.0)

100

  
  1. *Fisher’s exact test
  2. aNC/UR: No chemotherapy or Unknown response